Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501525 | 0.83 | DGAT1 (0.43) | DGAT1AKR1B1P2RX7PDPK1PYCR1 | |
| SCHEMBL23869529 | 0.82 | RIPK1 (0.48) | P2RX7MAPT | |
| SCHEMBL8444 | 0.82 | DGAT1 (0.46) | DGAT1AKR1B1P2RX7PDPK1PYCR1 | |
| SCHEMBL12709967 | 0.81 | CHRNA7 (0.46) | MAPTMEN1KMT2A | |
| SCHEMBL22539808 | 0.81 | P2RX7 (0.43) | P2RX7MAPTMEN1CYP1A2CYP2C9 | |
| SCHEMBL29574729 | 0.80 | AKR1B1 (0.52) | DGAT1AKR1B1P2RX7PDPK1MEN1 | |
| SCHEMBL5835 | 0.80 | AKR1B1 (0.52) | DGAT1AKR1B1P2RX7PDPK1MEN1 | |
| SCHEMBL1310479 | 0.79 | PYCR1 (0.50) | DGAT1AKR1B1P2RX7PDPK1PYCR1 | |
| SCHEMBL12069886 | 0.79 | MAPT (0.44) | DGAT1AKR1B1P2RX7PDPK1MAPT | |
| SCHEMBL31342163 | 0.79 | MAPT (0.44) | DGAT1AKR1B1P2RX7PDPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | DGAT1 598/4885AKR1B1 4260/4885P2RX7 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.